公开(公告)号：US07838000B2

公开(公告)日：2010-11-23

申请号：US11440746

申请日：2006-05-25

申请人： Thomas R. Scott ,  Heather P. Borick ,  Ginger A. Swire-Clark ,  William R. Marcotte, Jr. ,  Ashby B. Bodine

发明人： Thomas R. Scott ,  Heather P. Borick ,  Ginger A. Swire-Clark ,  William R. Marcotte, Jr. ,  Ashby B. Bodine

IPC分类号： A61K39/00 ,  A61K38/00

CPC分类号： C07K14/78 ,  A61K38/00 ,  A61K38/1777 ,  C07K2319/00

摘要： Disclosed are treatment agents and methods of treatment utilizing the agents directed toward diseases in which the disease causing pathogen includes α6β1 integrin receptors and/or α6β4 integrin receptors on the surface of the pathogen. In one embodiment, the disease can be breast cancer. The therapeutic agents disclosed include a polypeptide comprising at least a portion of the G domain of the laminin-5 α3 chain that has been shown to bind α6β1 integrin receptors and α6β4 integrin receptors. In one embodiment, the therapeutic agents can be fused or chimeric materials in which the laminin-5 α3 chain polypeptide has been chemically bound to another material that can be useful in the destruction or neutralization of the pathogen.

摘要翻译： 公开了治疗剂和治疗方法，其使用针对致病病原体的疾病的试剂在病原体表面包含α6和bgr1整联蛋白受体和/或α6＆bgr4整联蛋白受体。 在一个实施方案中，该疾病可以是乳腺癌。 所公开的治疗剂包括包含已经显示结合α6和bgr1整联蛋白受体和α6和bgr4整联蛋白受体的层粘连蛋白-5α3链的至少一部分G结构域的多肽。 在一个实施方案中，治疗剂可以是其中层粘连蛋白-5α3链多肽化学结合到另一种可用于破坏或中和病原体的材料的融合或嵌合物质。